Latest news with #LillyCatalyze360™
Business Wire
03-06-2025
- Business
- Business Wire
HAYA Therapeutics Moves San Diego Operations to Lilly Gateway Labs ® to Accelerate Development of RNA-Guided Therapeutics Platform
LAUSANNE, Switzerland & SAN DIEGO--(BUSINESS WIRE)-- HAYA Therapeutics, SA, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics that reprogram disease-driving cell states for rare, common, chronic and age-related diseases, announced that the company has relocated its U.S. site to Lilly Gateway Labs in San Diego, California, which is operated in partnership with Alexandria Real Estate Equities, Inc. 'Moving our U.S. site to Lilly Gateway Labs marks an important step in the scale-up of our operations,' said Samir Ounzain, Ph.D., Co-founder and CEO of HAYA Therapeutics. Share 'Moving our U.S. site to Lilly Gateway Labs marks an important step in the scale-up of our operations,' said Samir Ounzain, Ph.D., Co-founder and CEO of HAYA Therapeutics. 'The facility offers world-class infrastructure and access to a dynamic scientific environment, providing an ideal setting to continue to advance our RNA-guided therapeutics platform, which is designed to reprogram the root causes of disease with unmatched precision, speed and scalability.' Lilly Gateway Labs, which is part of the Lilly Catalyze360™ model, is a best-in-class innovation hub that connects early-stage biotech companies to the power of Lilly's expertise. The site offers cutting-edge laboratory space, operational support and access to an evolving ecosystem of biotech innovators. HAYA's San Diego office plays a central role in the company's laboratory operations, with a strong focus on advanced multi-modal functional genomics, one of the key components of HAYA's proprietary platform and its Regulatory Genome Atlas. The office will also support business and clinical development, including the advancement of HAYA's first-in-class long non-coding RNA (lncRNA)-targeting therapy HTX-001 for heart failure into the clinic with an initial focus on non-obstructive hypertrophic cardiomyopathy. HAYA recently announced a $65 million Series A financing to accelerate the development of RNA-guided therapeutics that target the regulatory genome to treat chronic and age-related diseases. The round was co-led by Sofinnova Partners and Earlybird Venture Capital, with participation from Eli Lilly and Company (Lilly) and Alexandria Venture Investments, the venture arm of Alexandria Real Estate Equities, Inc. At the core of HAYA's platform is the ability to map and decode the regulatory genome. HAYA has built the most comprehensive atlas of the regulatory genome by combining multi-modal functional genomics with proprietary computational and machine learning tools. This allows for the precise identification and modulation of pathogenic cell states across a range of diseases. Last year, HAYA announced a collaboration with Lilly focused on RNA-based drug targets for obesity and related metabolic disorders, making it one of the largest collaborations to date in the regulatory genome field. With its platform, HAYA is advancing a novel approach to develop next-generation precision medicines, and advance its mission of translating deep genomic, epigenomic and transcriptomic insights into novel disease-modifying therapies with potential to improve patients' outcomes by directly reprogramming the cellular drivers of disease. HAYA Therapeutics remains fully independent and retains all assets and intellectual property while at Lilly Gateway Labs. About HAYA Therapeutics HAYA Therapeutics is a precision medicines company developing programmable therapeutics targeting regulatory RNAs derived from the dark genome, a cell information processing unit, to reprogram pathological cell states for a broad range of diseases, including cardiovascular and metabolic diseases and cancer. The company is using its innovative platform to gain novel insights into the biology of disease cell states and the long non-coding RNAs (lncRNAs) that regulate them. HAYA's lead therapeutic candidate is HTX-001, in development for the treatment of heart failure. HAYA is also developing a pipeline of lncRNA-targeting precision therapies for the cell-specific treatment of diseases in other tissues. HAYA is headquartered at the life sciences park Biopôle in Lausanne, Switzerland with laboratory facilities at Lilly Gateway Labs, powered by Alexandria, in San Diego. For more information on the company, please visit our website at Follow us on X and LinkedIn.
Yahoo
17-04-2025
- Business
- Yahoo
BigHat Biosciences and Lilly Collaborate to Advance AI-Driven Antibody Therapeutics
Collaboration combines BigHat's AL/ML-powered Milliner™ platform with Lilly's expertise in drug discovery to develop high-quality next-generation antibodies. SAN MATEO, Calif., April 17, 2025--(BUSINESS WIRE)--BigHat Biosciences ("BigHat"), a biotechnology company with a machine learning (ML)-guided antibody discovery and development platform, announced a strategic collaboration with Eli Lilly and Company ("Lilly"). In this collaboration, BigHat will deploy its Milliner platform, a suite of state-of-the-art ML technologies integrated with a synthetic biology-based high-speed wet lab, to design and engineer therapeutic antibodies with superior functionality. BigHat and Lilly will collaborate to design and discover next-generation antibodies for up to two antibody therapeutic programs. This partnership aims to design, engineer, and develop antibodies with enhanced functionality and improved biophysical properties to create therapeutics that will benefit patients with chronic disease. "Partnering with Lilly represents an exciting opportunity to harness the full potential of AI-driven biologic design. By combining Lilly's deep expertise in drug discovery and development with BigHat's machine learning-powered Milliner platform, we can accelerate the advancement of truly differentiated, next-generation protein therapeutics," said Peyton Greenside, CEO and Co-founder of BigHat. This collaboration builds on BigHat's strategy to engage in value-generating strategic partnerships balanced with an exciting internal pipeline of proprietary therapeutics in the areas of oncology and immunology. BigHat's ML-powered platform is designed to tackle molecular engineering challenges and unlock the development of novel therapeutics for the improvement of patient outcomes. In addition to supporting the development of its partners' therapeutic programs, BigHat has built and advanced a pipeline of next-gen antibody-drug conjugates (ADCs) and functionally differentiated T-cell engagers (TCEs) across indications in both oncology and immunology. BigHat is advancing a next-generation ADC for GI cancers into the clinic in 2026. Lilly Catalyze360™ will provide support, while BigHat retains full global rights and control to the program. In addition to the antibody discovery collaboration and support for BigHat's ADC for GI cancers, Lilly will also make an equity investment in BigHat. This collaboration is part of the Lilly Catalyze360™ model, which is a comprehensive approach to empower early-stage biotech startups across all therapeutic areas by providing access to funding as well as world-class lab space and/or drug development talent and resources through its three pillars: Lilly Ventures, Lilly Gateway Labs®, and Lilly ExploR&D. About BigHat Biosciences BigHat Biosciences designs safer, more effective biologic therapies for patients using machine learning and synthetic biology. BigHat integrates a wet lab for high-speed characterization with machine learning technologies to guide the search for better antibodies and applies these design capabilities to develop new generations of safer and more effective treatments for patients suffering from today's most challenging diseases. BigHat Biosciences is a preclinical-stage drug discovery company that uses machine learning and synthetic biology to design safer, more effective antibodies for patients. We are a Series B-stage biotech outside San Francisco with a team-oriented, inclusive, and family-friendly culture. We have a pipeline of wholly-owned and partnered programs in therapeutic areas with high unmet need, such as cancer and inflammation. BigHat has raised >$100M from top investors, including Section 32, a16z, and 8VC. View source version on Contacts BigHat Biosciences Elizabeth Schwarzbachpartnering@ Sign in to access your portfolio
